March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
The Role Of Allo-antigen Presentation In Mice Penetrating Keratoplasty Controlled By Mhc Matching
Author Affiliations & Notes
  • Jun Yamada
    Ophthalmology, Meiji University of Integrative Medicine, Kyoto, Japan
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Takahiko Hayashi
    Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan
  • Junji Hamuro
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Satoshi Yamagami
    Section of Corneal Transplantation, Univ of Tokyo Graduate School of Med, Tokyo, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships  Jun Yamada, None; Takahiko Hayashi, None; Junji Hamuro, None; Satoshi Yamagami, None; Shigeru Kinoshita, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2377. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jun Yamada, Takahiko Hayashi, Junji Hamuro, Satoshi Yamagami, Shigeru Kinoshita; The Role Of Allo-antigen Presentation In Mice Penetrating Keratoplasty Controlled By Mhc Matching. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2377.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Reportedly, chimeric allografts enjoy graft survival, consisting of BALB/c or C3H/He corneal epithelium (Ep) over a B6 epithelial-denuded corneal stroma/endothelium (S/E), orthotopically placed on BALB/c hosts. Thus, corneal graft Ep, but not S/E, is believed to play a role in allosensitization in mice penetrating keratoplasty. Since the minorH alloantigens are the main target for allograft rejection, we examined the graft survival of MHC-matched chimeric allografts and investigated the minorH-specific allosensitization.

Methods: : Chimeric allografts consisting of B6 (H-2b), B10.D2 (H-2d), and BALB/c (H-2d) corneas were placed on BALB/c hosts. Immunized controls were prepared by subcutaneous insertion of central 2-mm diameter allogeneic Ep or S/E. Graft survivals and minorH alloantigen-specific delayed-type hypersensitivity response were evaluated.

Results: : BALB/c mice inserted with either B6-Ep, B10.D2-Ep, B6-S/E, or B10.D2-S/E corneas subcutaneously for 2 weeks displayed positive DTH (n=5 each). B6-Ep+BALB/c-S/E, but not B10.D2-Ep+BALB/c-S/E, grafted BALB/c mice displayed positive DTH at 4 weeks postoperative (n=10 each, 100% survival). Though BALB/c-Ep+B6-S/E allografts enjoyed graft survival (n=10, 90% survival), only 33% of BALB/c-Ep+B10.D2-S/E allografts survived indefinitely (n=15). BALB/c-Ep+B6-S/E grafted mice with healthy corneas displayed negative DTH response (n=7) at 4 weeks postoperative. In contrast, BALB/c-Ep+B10.D2-S/E grafted mice with healthy corneas displayed positive DTH response at 4 weeks postoperative (n=5). After ear challenge by B10.D2 splenocyte, all BALB/c-Ep+B6-S/E and BALB/c-Ep+B10.D2-S/E allografts were rejected. B10.D2-Ep+B6-S/E chimeric allografts survived indefinitely (n=10, 100% survival).

Conclusions: : Under orthotopical corneal allografts, MHC-mismatched corneal Ep possesses the capacity for sensitizing the host, but MHC-matched corneal Ep does not. In contrast, MHC-mismatched corneal S/E does not possess the capacity for sensitizing the host, but MHC-matched corneal S/E does. Donor-derived stromal CD11b-positive macrophages may present alloantigen under MHC-matched stromal allografts. Thus, it may be necessary to regulate stromal-layer allogeneic-antigen-presenting cells in MHC-matched allograft cases. In addition, the mechanism of the rejection in DSEAK can be explained.

Keywords: transplantation • immunomodulation/immunoregulation • immune tolerance/privilege 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×